Myasthenia gravis is a rare disease where the immune system attacks the communication between nerves and muscles, causing weakness. It often affects the muscles used for eye movement, facial ...

Kiran Bhavaraju-Sanka, MD, and Beth Stein, MD, focus on the best and most effective methods of engaging patients who have ...

Telitacicept met primary and all secondary endpoints, demonstrating clinically meaningful improvements in disease activity versus placebo~71.8% ...

Generalized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular junction autoantibodies, but a wide range of differences among patients affect the ...

World Myasthenia Gravis Day is celebrated every June 15 th. Myasthenia gravis (MG) is an autoimmune illness that affects approximately 1.5 to 2 million people globally. The disorder is characterized ...

Treatment with cemdisiran was associated with a statistically significant improvement in MG-ADL total score compared with placebo. Topline results were announced from a phase 3 trial evaluating ...

New guidelines and advocacy enhance myasthenia gravis treatment access, promoting proactive management and improved insurance coverage for diverse patient populations. There are key systemic factors ...

Claseprubart 300mg and 600mg Q2W doses both achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative ...